• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Valchlor (mechlorethamine) gel

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Valchlor (mechlorethamine) gel

  • Profile

Profile

Contact Information

Contact: Helsinn Birex Pharmaceuticals
Website: http://www.valchlor.com/

Currently Enrolling Trials

    Show More

    General Information

    Valchlor is a gel formulation of mechlorethamine, an alkylating agent that inhibits rapidly proliferating cells.

    Valchlor is specifically indicated for the topical treatment of stage IA and IB mycosisfungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

    Mechanism of Action

    Valchlor is a gel formulation of mechlorethamine, also known as nitrogen mustard, an alkylating agent that inhibits rapidly proliferating cells.

    Side Effects

    Adverse events associated with the use of Valchlor may include, but are not limited to, the following:

    • dermatitis
    • pruritus
    • bacterial skin infection
    • skin ulceration or blistering
    • hyperpigmentation

    Dosing/Administration

    Valchlor is supplied as a gel for topical administration. The recommendation is to apply a thin film of Valchlor gel once daily to affected areas of the skin. Upon improvement, treatment with Valchlor can be restarted at a reduced frequency of once every three days. If reintroduction of treatment is tolerated for at least one week, the frequency of application can be increased to every other day for at least one week and then to once daily application if tolerated.

    Clinical Trial Results

    The FDA approval of Valchlor gel was based on a randomized, multicenter, observer-blind, active-controlled, non-inferiority clinical trial of 260 subjects with stage IA, IB, and IIA mycosisfungoides-type cutaneous T-cell lymphoma (CTCL) who had received at least one prior skin-directed therapy. The subjects were stratified based on stage (IA versus IB and IIA) and then randomized to receive Valchlor 0.016 percent (equivalent to 0.02 percent mechlorethamine HCl) or Aquaphor-based mechlorethamine HCl 0.02 percent ointment (Comparator). Eighteen subjects were excluded from the efficacy analysis due to protocol violations involving randomization at a single site. Study drug was applied topically on a daily basis for 12 months. Concomitant use of topical corticosteroids was not permitted during the study. The mean daily usage of Valchlor gel was 2.8 g. The maximum daily usage was 10.5 g. Subjects were evaluated for a response on a monthly basis for the first six months and then every two months for the last six months using the Composite Assessment of Index Lesion Severity (CAILS) score. A response was defined as greater than or equal to 50 percent reduction in baseline CAILS score, which was confirmed at the next visit at least four weeks later. A complete response was defined as a confirmed CAILS score of 0 (no symptoms). Subjects were also evaluated using the Severity Weighted Assessment Tool (SWAT). A response was defined as greater than or equal to 50 percent reduction in baseline SWAT score, which was confirmed at the next visit at least four weeks later. Sixty percent (60 percent) of the subjects on the Valchlor arm and 48 percent of subjects on the comparator arm achieved a response based on the CAILS score. Valchlor was not inferior to the comparator based on a CAILS overall response rate ratio of 1.24. Complete responses constituted a minority of the CAILS or SWAT overall responses. The onset of CAILS overall response for both treatment arms showed a wide range from one to 11 months.

     

    Approval Date: 2013-08-01
    Company Name: Ceptaris Therapeutics
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing